UK's Poor Uptake Of New Drugs May Be Hitting Clinical Trial Investment
Executive Summary
The pharmaceutical industry wants the UK to improve its uptake of innovative medicines in order to spur investment in clinical trials under the government's life sciences sector deal. One industry representative says companies are already questioning the ethics of conducting trials in a country where their drug might not be commercialized.
You may also be interested in...
RWE and Clinical Trials To Take Center Stage In UK Sector Deal Prospects
Some of the loudest messages from UK government's Life Science Sector Deal was the importance of using real world evidence - and the uniqueness the British health ecosystem can offer to trail blazing innovation.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.